Anne-Lise Septans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Lise Septans has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Frédéric Maloisel
Clinique Sainte Anne, Strasbourg, France
3 shared publications - Katell Le Du
18Hôpital Privé du Confluent, Nantes, France
3 shared publications - Adrien Chauchet
Department of Hematology, University Hospital, Besançon, France
2 shared publications - Arnaud Saint-Lezer
Department of Hematology, Mont de Marsan Hospital, Mont de Marsan, France
2 shared publications - Cédric Rossi
Department of Hematology, Centre Hospitalier Universitaire de Dijon, Dijon, France
2 shared publications - Fontanet Bijou
Institut Bergonié, Bordeaux, France
2 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Impact of electronic monitoring of adverse events in patients receiving R-CHOP therapy for diffuse large B-cell lymphoma: open-label prospective randomized controlled phase 3 trial (EMILY) (Preprint)
BACKGROUND Progression is the leading cause of death among patients receiving first line treatment for diffuse large B-cell lymphoma. Some patients die from treatment-related toxicity, secondary cancers, or comorbidities, particularly cardiovascular conditions. The early detection of these events could improve quality of life and event-free survival. OBJECTIVE This study aims to describe the adverse events that have occurred and the methods used to manage them, comparing an electronic application-assisted physician approach with standard follow-up procedures. METHODS An open-label prospective, randomized, controlled phase 3 trial was conducted to compare the impact of a web-based application for monitoring events occurring during rituximab combined with cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (R-CHOP) treatment (experimental group) with that of standard monitoring (control group). RESULTS A total of 62 patients were included in the study, with a median age of 62.0 years (Q1–Q3: 50.0–74.0). Thirty-one patients were randomized to each group (1:1 randomization). The study was terminated prematurely on October 17, 2024, due to bankruptcy of the unit responsible for promoting clinical trials. The median follow-up was 8.3 months (Q1–Q3: 1–24.2 months). In total, 617 events were reported (403 in the experimental group and 214 in the control group) (P<.01). About 340 events, including 238 in the experimental group and 102 in the control group, required intervention (P<.01). The median numbers of events per patient were 14 in the experimental group (Q1–Q3: 4–24), and 7 in the control group (Q1–Q3: 3–10) (P=.05). The mean times to treatment were 7.7 days in the overall population, 4.5 days in the experimental group, and 15.6 days in the control group (P=.14). Thirty-one events, including 13 in the experimental group and 18 in the control group, required hospitalization (P<.01). The event-free survival rates at the 12-months follow-up were 61.1% in the experimental group and 68.7% in the control group (P=.40). CONCLUSIONS Event monitoring via a web application was feasible in patients with diffuse large B-cell lymphoma, with a higher number of reports in the experimental group. Compared with the control group, the experimental group had a lower proportion of events requiring hospitalization. However, considering the premature termination and the descriptive nature of the study, these results should be interpreted as exploratory CLINICALTRIAL ClinicalTrials.gov NCT05298293
- 22 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImpact of electronic monitoring of adverse events in patients receiving R-CHOP therapy for diffuse large B-cell lymphoma: open-label prospective randomized controlled phase 3 trial (EMILY) (Preprint)
BACKGROUND Progression is the leading cause of death among patients receiving first line treatment for diffuse large B-cell lymphoma. Some patients die from treatment-related toxicity, secondary cancers, or comorbidities, particularly cardiovascular conditions. The early detection of these events could improve quality of life and event-free survival. OBJECTIVE This study aims to describe the adverse events that have occurred and the methods used to manage them, comparing an electronic application-assisted physician approach with standard follow-up procedures. METHODS An open-label prospective, randomized, controlled phase 3 trial was conducted to compare the impact of a web-based application for monitoring events occurring during rituximab combined with cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (R-CHOP) treatment (experimental group) with that of standard monitoring (control group). RESULTS A total of 62 patients were included in the study, with a median age of 62.0 years (Q1–Q3: 50.0–74.0). Thirty-one patients were randomized to each group (1:1 randomization). The study was terminated prematurely on October 17, 2024, due to bankruptcy of the unit responsible for promoting clinical trials. The median follow-up was 8.3 months (Q1–Q3: 1–24.2 months). In total, 617 events were reported (403 in the experimental group and 214 in the control group) (P<.01). About 340 events, including 238 in the experimental group and 102 in the control group, required intervention (P<.01). The median numbers of events per patient were 14 in the experimental group (Q1–Q3: 4–24), and 7 in the control group (Q1–Q3: 3–10) (P=.05). The mean times to treatment were 7.7 days in the overall population, 4.5 days in the experimental group, and 15.6 days in the control group (P=.14). Thirty-one events, including 13 in the experimental group and 18 in the control group, required hospitalization (P<.01). The event-free survival rates at the 12-months follow-up were 61.1% in the experimental group and 68.7% in the control group (P=.40). CONCLUSIONS Event monitoring via a web application was feasible in patients with diffuse large B-cell lymphoma, with a higher number of reports in the experimental group. Compared with the control group, the experimental group had a lower proportion of events requiring hospitalization. However, considering the premature termination and the descriptive nature of the study, these results should be interpreted as exploratory CLINICALTRIAL ClinicalTrials.gov NCT05298293
- Open Access
- 6 May 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11 (1) , e65960
Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)
Background: Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse. Objective: This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire. Methods: We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis. Results: A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm (P=.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm (P<.001), with a median follow-up of 7.7 (range 2.8‐20.6) months and 6.7 (range 1.9‐16.4) months (P=.94), respectively. Statistical analysis was conducted after including the 40th patient, which showed no superiority of the experimental arm over the control arm. The study was therefore stopped after the 52nd patient was enrolled. Conclusions: The primary objective was not reached; however, patient-reported outcome measures remain essential for detecting adverse events in patients with cancer, and the electronic monitoring method needs to demonstrate its effectiveness and comply with international safety guidelines.
- 6 May 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11 (1) , e65960
Open AccessComparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)
Background: Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse. Objective: This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire. Methods: We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis. Results: A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm (P=.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm (P<.001), with a median follow-up of 7.7 (range 2.8‐20.6) months and 6.7 (range 1.9‐16.4) months (P=.94), respectively. Statistical analysis was conducted after including the 40th patient, which showed no superiority of the experimental arm over the control arm. The study was therefore stopped after the 52nd patient was enrolled. Conclusions: The primary objective was not reached; however, patient-reported outcome measures remain essential for detecting adverse events in patients with cancer, and the electronic monitoring method needs to demonstrate its effectiveness and comply with international safety guidelines.
- Open Access
- 31 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Randomized trial comparing a web-based follow-up with routine surveillance in high-risk lymphoma: results of the phase 3 Sentinel Lymphoma trial. (Preprint)
BACKGROUND Relapse is a major event for lymphoma patients. Early detection could have an impact on quality of life and overall survival. Patient-related outcome measures have already demonstrated clinical benefit for lung cancer patients. Evidence is lacking for lymphoma patients. We proposed to evaluate the impact of a web-application follow-up for lymphoma patients at high risk of relapse. OBJECTIVE The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. METHODS We planned a prospective, randomized phase 3 trial, comparing web-based follow-up (experimental arm) to a standard arm (control arm). Eligible patients were 18 years of age and older with lymphoma at high risk of relapse. Patients could have T-cell lymphoma in first partial or complete response, Hodgkin lymphoma in second partial or complete response, or diffuse large B-cell lymphoma in first partial or complete response with a revised high IPI score (≥3) or in second partial or complete response. The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. An interim analysis was performed at the inclusion of the first 40 patients. RESULTS A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France: 27 in the experimental arm and 25 in the control arm. Median follow-up was 21.3 months (range, [1.3-25.6] months). One hundred and twenty-one events were reported during the study period. Most events were reported in the experimental arm (83/119, 69.7%) compared to 30.2% (36/119) in the control arm, with a mean number of events per patient of 3.5 in the experimental arm and 1.8 in the control arm (p=.0041). Progression and infection were most frequently reported events. Nineteen patients relapsed during follow-up: 6 in the experimental arm and 13 in the standard arm (p<.001), with a median follow-up of 7.7 (range, [2.8-20.6] months) and 6.7 (range [1.9-16.4] months) (p=.94) respectively. Nine out of 26 patients (34.6%) in the experimental group did not receive their electronic questionnaire and the supplier was unable to remedy this. The interim analysis showed that there was no difference in the diagnosis of events. CONCLUSIONS PRO measures remain essential, but the electronic monitoring method must comply with international safety guidelines. CLINICALTRIAL ClinicalTrials.gov NCT 03154710
- 31 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessRandomized trial comparing a web-based follow-up with routine surveillance in high-risk lymphoma: results of the phase 3 Sentinel Lymphoma trial. (Preprint)
BACKGROUND Relapse is a major event for lymphoma patients. Early detection could have an impact on quality of life and overall survival. Patient-related outcome measures have already demonstrated clinical benefit for lung cancer patients. Evidence is lacking for lymphoma patients. We proposed to evaluate the impact of a web-application follow-up for lymphoma patients at high risk of relapse. OBJECTIVE The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. METHODS We planned a prospective, randomized phase 3 trial, comparing web-based follow-up (experimental arm) to a standard arm (control arm). Eligible patients were 18 years of age and older with lymphoma at high risk of relapse. Patients could have T-cell lymphoma in first partial or complete response, Hodgkin lymphoma in second partial or complete response, or diffuse large B-cell lymphoma in first partial or complete response with a revised high IPI score (≥3) or in second partial or complete response. The primary endpoint was to demonstrate a 30% superiority in the detection of significant events in the experimental arm compared with the control arm over a 6-month follow-up. An interim analysis was performed at the inclusion of the first 40 patients. RESULTS A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France: 27 in the experimental arm and 25 in the control arm. Median follow-up was 21.3 months (range, [1.3-25.6] months). One hundred and twenty-one events were reported during the study period. Most events were reported in the experimental arm (83/119, 69.7%) compared to 30.2% (36/119) in the control arm, with a mean number of events per patient of 3.5 in the experimental arm and 1.8 in the control arm (p=.0041). Progression and infection were most frequently reported events. Nineteen patients relapsed during follow-up: 6 in the experimental arm and 13 in the standard arm (p<.001), with a median follow-up of 7.7 (range, [2.8-20.6] months) and 6.7 (range [1.9-16.4] months) (p=.94) respectively. Nine out of 26 patients (34.6%) in the experimental group did not receive their electronic questionnaire and the supplier was unable to remedy this. The interim analysis showed that there was no difference in the diagnosis of events. CONCLUSIONS PRO measures remain essential, but the electronic monitoring method must comply with international safety guidelines. CLINICALTRIAL ClinicalTrials.gov NCT 03154710
- Open Access
- 2 August 2024
- Published by Wiley in Physica Status Solidi (RRL) – Rapid Research Letters
- Vol. 18 (12)
Magnetism of Iron Oxide Nanoparticles: From Atomic Order to Complexity at the Mesoscopic Scale
Zn‐substituted iron oxide nanoparticles of ≈5 nm in diameter are synthetized by a microwave‐assisted thermal decomposition method. The addition of ethylene glycol results in a size increase to 22 nm. Cationic disorder has been observed by electron energy loss spectroscopy–scanning transmission electron microscopy. Using Mössbauer spectrometry combined with Rietveld analysis, the complete cationic and vacancies repartition in the lattice is determined, as well as the canting of magnetic moments. This allows the magnetic moment to be calculated, in good agreement with that measured. The alternating current magnetic susceptibility is modeled by the Néel–Brown and the Coffey models, showing some discrepancy between these two approaches which is discussed. The largest particles show a complex morphology involving an oriented attachment mechanism of smaller units. Their cationic disorder and internal porosity have been evidenced and quantified, and the work shows that despite these defects they behave rather as magnetically blocked nanoparticles.
- 2 August 2024
- Published by Wiley in Physica Status Solidi (RRL) – Rapid Research Letters
- Vol. 18 (12)
Open AccessMagnetism of Iron Oxide Nanoparticles: From Atomic Order to Complexity at the Mesoscopic Scale
Zn‐substituted iron oxide nanoparticles of ≈5 nm in diameter are synthetized by a microwave‐assisted thermal decomposition method. The addition of ethylene glycol results in a size increase to 22 nm. Cationic disorder has been observed by electron energy loss spectroscopy–scanning transmission electron microscopy. Using Mössbauer spectrometry combined with Rietveld analysis, the complete cationic and vacancies repartition in the lattice is determined, as well as the canting of magnetic moments. This allows the magnetic moment to be calculated, in good agreement with that measured. The alternating current magnetic susceptibility is modeled by the Néel–Brown and the Coffey models, showing some discrepancy between these two approaches which is discussed. The largest particles show a complex morphology involving an oriented attachment mechanism of smaller units. Their cationic disorder and internal porosity have been evidenced and quantified, and the work shows that despite these defects they behave rather as magnetically blocked nanoparticles.
- 24 September 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Magnetics Letters
- Vol. 11 (1949307X) , 1-5
Evidence of the Superparamagnetic State in the Zero-Field Microwave Susceptibility Spectra of Ferrimagnetic Nanoparticles
Static and dynamic magnetic properties of Zn0.4Fe2.6O4 nanoparticles synthesized by thermal decomposition have been investigated. Two ranges of diameter have been used: small particles (diameter about 6.2 nm) and larger ones (diameter about 22.4 nm). The nanoparticle microstructure has been characterized by transmission electron microscopy. The temperature dependence of the zero-field dynamic permeability for both nanoparticle sizes has been studied, revealing a superparamagnetic state for the small ones. Effects of the nanoparticle size on the dynamic permeability have been studied, and linked to the superparamagnetic state. A dynamic susceptibility model has been found to reproduce the experimental behavior as well as its temperature dependence.
- 24 September 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Magnetics Letters
- Vol. 11 (1949307X) , 1-5
Evidence of the Superparamagnetic State in the Zero-Field Microwave Susceptibility Spectra of Ferrimagnetic Nanoparticles
Static and dynamic magnetic properties of Zn0.4Fe2.6O4 nanoparticles synthesized by thermal decomposition have been investigated. Two ranges of diameter have been used: small particles (diameter about 6.2 nm) and larger ones (diameter about 22.4 nm). The nanoparticle microstructure has been characterized by transmission electron microscopy. The temperature dependence of the zero-field dynamic permeability for both nanoparticle sizes has been studied, revealing a superparamagnetic state for the small ones. Effects of the nanoparticle size on the dynamic permeability have been studied, and linked to the superparamagnetic state. A dynamic susceptibility model has been found to reproduce the experimental behavior as well as its temperature dependence.